Fecal Occult Testing Market Report by Test Type (Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, Immuno-FOB ELISA Test), End User (Hospitals, Clinical Diagnostic Laboratories, Physician Office Laboratories), and Region 2024-2032
The global fecal occult testing market size reached US$ 1,367.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 2,031.8 Million by 2032, exhibiting a growth rate (CAGR) of 4.4% during 2024-2032.
A fecal occult blood test (FOBT) is a noninvasive procedure used to detect hidden blood in the feces or stool. It is performed by collecting samples using cards and flushable reagent pads or tissues. These samples are sent to the laboratory for testing and are used to diagnose conditions such as hemorrhoids, diverticulosis, ulcers, colitis, benign tumors and colon polyps or cancer, which cause bleeding in the digestive tract. At present, the growing awareness about early screening is promoting the adoption of fecal occult testing, as it enables quick medical decisions, provides effective healthcare, and leads to improved quality of life and the reduced mortality rate.
The rising focus on integrated health services for improved patient experience and health outcomes, in confluence with the increasing inclination towards point-of-care diagnostics (POCD), represents one of the key factors stimulating the market growth. Apart from this, the rising geriatric population is accelerating the growth of the market as the risk of contracting diseases increases with age. As a result, governing agencies of various countries are implementing several FOBT screening programs for older adults. Furthermore, the widespread adoption of minimally invasive (MI) procedures is contributing to the growth of the market. Besides this, immunochemical fecal occult blood tests (iFOBTs or FITs) are gaining traction as they are easy to use and clinically more sensitive to cancers and advanced adenomas. The easy availability of FOBT devices at online retail stores is anticipated to create a positive impact on the market growth in the upcoming years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global fecal occult testing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on test type and end user.
Breakup by Test Type:
Guaiac FOB Stool Test
Immuno-FOB Agglutination Test
Lateral Flow Immuno-FOB Test
Immuno-FOB ELISA Test
Breakup by End User:
Hospitals
Clinical Diagnostic Laboratories
Physician Office Laboratories
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Beckman Coulter Inc. (Danaher Corporation), Biohit Oyj, EDP Biotech Corporation, Eiken Chemical Co. Ltd., Epigenomics AG, Quest Diagnostics Incorporated, Quidel Corporation and Randox Laboratories Ltd.
Key Questions Answered in This Report:
How has the global fecal occult testing market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global fecal occult testing market?
What are the key regional markets?
What is the breakup of the market based on the test type?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global fecal occult testing market and who are the key players?
What is the degree of competition in the industry?